Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer’s disease treatment
Alzheimer’s disease (AD) is characterized by a long preclinical phase lasting more than a decade before the onset of its clinical phase of mild cognitive impairment (MCI) or dementia. Recent advances in psychedelic research underscore numerous neuroplastogenic and anti-inflammatory alterations induc...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Dementia |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/frdem.2025.1605051/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|